# 3TBiosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/3tbiosciences

- Industry: Healthcare Specialists
- Headquarters: South San Francisco, US
- Website: www.3tbiosciences.com
- Total disclosed funding: $61M
- Latest round: Series A (Jul 9, 2021)
- Investors on record: 3

## About

3T Biosciences, Inc. focuses on developing innovative T-cell receptor (TCR) therapeutics aimed at enhancing immunotherapy treatments for cancer and other diseases using advanced biotechnological solutions.Founded in 2017 in South San Francisco, US, 3T Biosciences specializes in TCR therapeutics. With two deals completed, their latest funding round was a Series A in July 2021, where they raised USD 48.53 mn led by Westlake Village BioPartners, with Lightspeed Venture Partners participating. Founders Leah Sibener and Marvin Gee, along with CEO John Connolly, drive the company’s mission with a vision for growth in the biopharmaceutical sector.3T Biosciences specializes in transformative T-cell receptor (TCR) therapeutics, focusing on TCR target identification and therapeutic discovery. Their core offerings revolve around advanced biotechnological solutions aimed at enhancing immunotherapy treatments for cancer and other diseases. The company employs proprietary technologies to discover and develop TCRs that can recognize and bind to specific antigens presented by cancer cells, which is crucial for effective targeted therapies. These products are particularly relevant for oncologists and researchers in the biopharmaceutical sector, seeking innovative approaches to improve patient outcomes. 3T Biosciences caters primarily to markets in North America and Europe, where demand for advanced immunotherapeutic solutions is growing among healthcare providers and research institutions.3T Biosciences' revenue model is predominantly centered around partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers. The company engages in B2B transactions where they license their proprietary technologies and therapeutics to partner organizations, allowing for shared development and commercialization efforts. This structure promotes innovation while providing a revenue stream from licensing fees and potential milestone payments upon achieving specific clinical development targets. Their flagship products include proprietary TCRs that are designed for use in therapeutic applications, although specific pricing and transaction terms are established on a case-by-case basis based on the scope of collaboration.In July 2021, 3T Biosciences raised USD 48.53 mn in Series A funding, which will be utilized to accelerate the development of novel TCR targets into clinical settings. The company is focusing on expanding into new markets, particularly in Europe, where they see significant potential for their immunotherapy solutions. The recent funding will support these expansion efforts and enhance their capabilities in the therapeutic domain.

## Funding rounds

- Series A, Jul 9, 2021, $49M — Lightspeed Venture Partners, Westlake Village BioPartners
- Seed, Oct 4, 2017, $12M — Valar

## Investors

- Valar (https://capitalatlas.ai/funds/valar) — Seed
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A